Press Release

PhRMA Statement on Partnership to Support Innovation

PhRMA February 24, 2010

Washington, D.C. (February 24, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding efforts to encourage medical progress:

“PhRMA applauds the collaborative initiative announced today by the National Institutes of Health and the Food and Drug Administration. We support the partnership’s goal of bringing needed medicines to market more quickly, while ensuring that sound science remains at the forefront of innovative drug development and regulation.

“Largely as a result of the world-leading innovation of America’s pharmaceutical research and biotechnology companies, patients now have more new medicines to fight a wide array of diseases and medical conditions, including debilitating and life-threatening chronic diseases. Chronic medical conditions consume 75 cents of every dollar of healthcare spending.

“America’s pharmaceutical research and biotechnology companies lead the world in discovering and developing innovative medical therapies that have revolutionized health care.

“Cancer patients are living, on average, three years longer – and 83 percent of those survival rate gains are due to new treatments, including medicines. Heart failure and heart attack deaths fell by nearly half from 1999 to 2005. Blood pressure medicines prevented 86,000 premature deaths from cardiovascular disease and avoided 833,000 hospitalizations for heart attack and stroke, according to a 2007 study in Health Affairs. And, since the advent of highly active anti-retroviral therapy in 1995, the annual number of U.S. deaths due to AIDS has plummeted by more than 70 percent.

“These and untold other medical advances were driven by U.S.-based medical innovation. According to the Tufts Center for the Study of Drug Development, a staggering 75 percent of all new drugs approved worldwide from 2005 to 2007 were first introduced in the U.S.

“For that reason, PhRMA is heartened by a new partnership that harnesses the strength of the nation’s preeminent public health agencies to help speed the transformation of promising lab concepts into actual medications that help patients live longer, healthier and more productive lives.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit:

For information on the danger of imported drugs, visit: